Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andrea Gray

Nurse Practitioner, Adult Health Lees Summit, MO Nurse Practitioner

NPI 1316360803 CMS profile 10745582

110 Ne Saint Lukes Blvd, Suite 530, Lees Summit, MO 64086

Open in the dashboard

General payments

$6,187

353 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrea Gray of Lees Summit, MO is reported in the CMS Open Payments database as having received $6,187 across 353 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,395 78
2024 General $1,784 98
2023 General $1,509 80
2022 General $929 58
2021 General $570 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrea Gray
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Andrea Gray were reported at $1,395. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Andrea Gray Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $570 $138 $43–$438 $132
2022 $929 $165 $54–$494 $149
2023 $1,509 $178 $61–$549 $160
2024 $1,784 $186 $62–$575 $164
2025 $1,395 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,478 103 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,411 88 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $878 47 payments
  4. Janssen Biotech, Inc. $735 31 payments
  5. Regeneron Healthcare Solutions, Inc. $409 16 payments
  6. Merck Sharp & Dohme Corporation $199 10 payments
  7. Ardelyx, Inc. $180 9 payments
  8. Pfizer Inc. $166 10 payments
  9. Genzyme Corporation $149 6 payments
  10. Lilly USA, LLC $103 5 payments
  11. Other $479 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,000 349 payments
  2. Education $187 4 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $1,163 75 payments
  2. RINVOQ $635 47 payments
  3. ENTYVIO $590 29 payments
  4. LINZESS $563 36 payments
  5. STELARA $524 24 payments
  6. CREON $522 33 payments
  7. TRULANCE $369 21 payments
  8. SKYRIZI $354 26 payments
  9. DUPIXENT $320 12 payments
  10. TREMFYA $212 7 payments
  11. Other $2,940 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,315

Median for Nurse Practitioner: 389

Drug cost

$464,964

Median for Nurse Practitioner: $21,885

Branded share of claims

18.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 12 $329,358
Linzess Linaclotide Brand 41 $47,105
Creon Lipase/Protease/Amylase Brand 11 $22,253
Trulance Plecanatide Brand 17 $12,616
Mesalamine Generic 32 $8,492
Dexlansoprazole Dr Dexlansoprazole Brand 18 $6,407
Pantoprazole Sodium Generic 288 $5,098
Colestipol Hcl Generic 51 $4,507
Esomeprazole Magnesium Generic 32 $4,428
Lubiprostone Generic 17 $3,775

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$42,511

Medicare's payments for the services billed

Medicare patients

433

Average age 74

Services billed

586

274 women, 159 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 36%
Diabetes 33%
Chronic kidney disease 32%
Depression 28%
Atrial fibrillation 24%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $266
$266 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $192
  • GENZYME CORPORATION $28
$220 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $165
$165 — —
RINVOQ
  • AbbVie, Inc. $161
$161 — —
LINZESS
  • AbbVie, Inc. $128
$128 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

353 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record